Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The clinical research about Joint detection of toxicity and efficacy related marker of chemotherapy drug in individual therapy of colorectal cancer

ABSTRACT: Interventions: case series:FOLFIRI?? Primary outcome(s): safety;Time to progression Study Design: Case series

DISEASE(S): Colorectal Cancer

PROVIDER: 2668930 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Anti-cancer drug sensitive DNA methylation marker research

Project description:Genome wide DNA methylation profiling of normal and colon cancer and assosiation study between anti-cancer drug respond group and non-respond group. The Illumina Infinium 27k Human DNA methylation Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 27,000 CpGs in 118 paired anti-cancer drug response tested colon cancer and adjacent normal tissues Bisulphite converted DNA from the 248 samples were hybridised to the Illumina Infinium 27k Human Methylation Beadchip v1.2

2011-12-31 | E-GEOD-27130 | biostudies-arrayexpress

Anti-cancer drug sensitive DNA methylation marker research

2011-12-31 | GSE27130 | GEO

A prospective study of irinotecan drug-eluting beads (DEBIRI) combined with FOLFIRI in patients after failure of FOLFOX with colorectal liver metastases

Project description:Interventions: Case Series:DEBIRI+FOLFIRI Primary outcome(s): DCR Study Design: Case series

| 2679864 | ecrin-mdr-crc

Research for observation of mesenteric vessels and related anatomic variations by ultrathin CT

Project description:Interventions: Case series:CT scan Primary outcome(s): Vascular anatomical variation Study Design: Sequential

| 2691053 | ecrin-mdr-crc

An open, non-interventional study based on the drug sensitivity detection technology of tumor patient-derived organoids

Project description:Interventions: case series:Nil Primary outcome(s): pdo modeling success rate(%) Study Design: Sequential

| 2734714 | ecrin-mdr-crc

Establishment of evaluation system of toxicity and side effects of chemotherapy for colorectal cancer and development of new early warning markers related to therapeutic effect

Project description:Interventions: Case series:Chemotherapy Primary outcome(s): toxic and adverse effects Study Design: Sequential

| 2697299 | ecrin-mdr-crc

Project description:cefepime-zidebactam case series

| PRJNA1174875 | ENA

Clinical study for apatinib combined with tegafur in the treatment of advanced colorectal cancer and analysis of related prognostic factors

Project description:Interventions: Case series:Apatinib combined with tegafur Primary outcome(s): progression-free survival Study Design: Case series

| 2679969 | ecrin-mdr-crc

MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity.

Project description:Emerging hepatic models for the study of drug-induced toxicity include pluripotent stem cell-derived hepatocyte-like cells (HLCs) and complex hepatocyte-non-parenchymal cellular coculture to mimic the complex multicellular interactions that recapitulate the niche environment in the human liver. However, a specific marker of hepatocyte perturbation, required to discriminate hepatocyte damage from non-specific cellular toxicity contributed by non-hepatocyte cell types or immature differentiated cells is currently lacking, as the cytotoxicity assays routinely used in in vitro toxicology research depend on intracellular molecules which are ubiquitously present in all eukaryotic cell types. In this study, we demonstrate that microRNA-122 (miR-122) detection in cell culture media can be used as a hepatocyte-enriched in vitro marker of drug-induced toxicity in homogeneous cultures of hepatic cells, and a cell-specific marker of toxicity of hepatic cells in heterogeneous cultures such as HLCs generated from various differentiation protocols and pluripotent stem cell lines, where conventional cytotoxicity assays using generic cellular markers may not be appropriate. We show that the sensitivity of the miR-122 cytotoxicity assay is similar to conventional assays that measure lactate dehydrogenase activity and intracellular adenosine triphosphate when applied in hepatic models with high levels of intracellular miR-122, and can be multiplexed with other assays. MiR-122 as a biomarker also has the potential to bridge results in in vitro experiments to in vivo animal models and human samples using the same assay, and to link findings from clinical studies in determining the relevance of in vitro models being developed for the study of drug-induced liver injury.

| S-EPMC4349141 | biostudies-literature

Apatinib Mesylate Tablets of joint mFOLFOX6 neoadjuant chemotherapy in locally advanced colorectal cancer clinical research

Project description:Interventions: Case series:Apatinib Mesylate Tablets of joint mFOLFOX6 neoadjuant chemotherapy Primary outcome(s): pathologic complete response;Objective response rate;Drop period to ensure operation resection Study Design: Case series

| 2670768 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data